Davey R J
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
Transfus Med Rev. 1988 Sep;2(3):151-60. doi: 10.1016/s0887-7963(88)70040-1.
The ability to radiolabel and follow the red cell in vivo has been of great value to the clinician and the investigator. An understanding of the advantages and disadvantages of the three nuclides used in transfusion medicine--51Cr, 99mTc, and 111In--allows the selection of the appropriate nuclide for the task at hand. For red cell life-span studies and for red cell survivals extending over one hour, 51Cr is the label of choice. The most accurate method for determining the zero-time (100% survival) point for a life span or survival study is to ascertain the RCM of the subject using autologous red cells labeled with another nuclide, preferably 99mTc. RCM studies done independently from a 51Cr survival should be performed using 111In labeled red cells. Red cell survivals are most often used to determine transfusion compatibility or to evaluate blood storage systems. There are important differences in the conduct and interpretation of red cell survivals for these two purposes. Although other promising methods for evaluating the in vivo survival of red cells are under investigation, it is likely that the radiotracers now available will continue to play a primary role in performing these studies in the future.
在体内对红细胞进行放射性标记并追踪的能力，对临床医生和研究人员来说具有重大价值。了解输血医学中使用的三种核素——51铬、99m锝和111铟——的优缺点，有助于为手头的任务选择合适的核素。对于红细胞寿命研究以及持续时间超过一小时的红细胞存活研究，51铬是首选标记物。确定寿命或存活研究的零时（100%存活）点的最准确方法，是使用用另一种核素（最好是99m锝）标记的自体红细胞来确定受试者的红细胞质量（RCM）。与51铬存活研究独立进行的RCM研究，应使用111铟标记的红细胞。红细胞存活研究最常用于确定输血相容性或评估血液储存系统。对于这两个目的，红细胞存活研究的实施和解释存在重要差异。尽管目前正在研究其他评估红细胞体内存活的有前景的方法，但现有的放射性示踪剂很可能在未来进行这些研究时继续发挥主要作用。
